Helius Med Technolog (HSDT) 0.9320 $HSDT
Helius Medical Technologies Appoints Thomas Griffin to Board of Directors and Chairman of the Audit Committee
Marketwire Canada - Mon Aug 08, 8:01AM CDT
NEWTOWN, PENNSYLVANIA--(Marketwired - Aug 8, 2016) - Helius Medical Technologies, Inc. (TSX:HSM)(OTCQB:HSDT) ("Helius" or the "Company"
a company focused on the treatment of neurological symptoms caused by disease or trauma, announced today that Thomas Griffin will join the Board of Directors, effective immediately. Mr. Griffin will also serve as Chairman of the Audit Committee.
ENTL: 18.13 (-0.22), HSM.TO: 1.16 (unch)
Helius Medical Announces Results from a Case Series of Subjects With Advanced MS
Marketwire Canada - Tue Jun 21, 8:03AM CDT
NEWTOWN, PENNSYLVANIA--(Marketwired - Jun 21, 2016) - Helius Medical Technologies, Inc. (TSX:HSM)(TSX:HSM.S)(OTCQB:HSDT) ("Helius" or the "Company" is pleased to announce the results of a case series of individuals with advanced symptoms of Multiple Sclerosis (MS) treated with PoNS™ Therapy.
HSM.TO: 1.16 (unch), HSM-S.TO: 1.15 (-0.12)
Helius Medical Announces Proceeds of $1.4 Million From Exercise of Warrants
Marketwired - Mon Jun 06, 8:03AM CDT
NEWTOWN, PENNSYLVANIA--(Marketwired - Jun 6, 2016) - Helius Medical Technologies, Inc. (TSX:HSM)(OTCQB:HSDT) ("Helius" or the "Company" a medical technology company focused on the treatment of neurological symptoms caused by disease or trauma, is pleased to announce that it received proceeds of CDN $1,825,600 (approximately US$1,409,947) from the exercise of certain warrants issued in 2014, all of which was received after the Company's fiscal year end on March 31, 2016.
HSM.TO: 1.16 (unch)
Helius Medical Technologies Restates and Re-Files Historical Financial Statements for Non-Cash Reclassification of Warrants
Marketwired - Tue Apr 26, 4:06PM CDT
Helius Medical Technologies, Inc. (TSX: HSM)(OTCQB: HSDT) ("Helius" or the "Company" - The Company is issuing the following press release to clarify its disclosure.
HSM.TO: 1.16 (unch)
CSE: 2016-0408 - Delist - Helius Medical Technologies Inc. (HSM)
Marketwired - Mon Apr 18, 10:30AM CDT
The common shares of Helius Medical Technologies Inc. will be delisted at the market close today, April 18, 2016.
IIROC Trade Resumption - Helius Medical Technologies, Inc.
Newsfile Corp - Mon Apr 18, 8:25AM CDT
Trading resumes in:
IIROC Trade Resumption - HSM.S
CNW Group - Mon Apr 18, 8:24AM CDT
Trading resumes in:
IIROC Trade Halt - Helius Medical Technologies, Inc. Reg S Shares
Newsfile Corp - Mon Apr 18, 7:27AM CDT
The following issues have been halted by IIROC:
Helius Medical Technologies Restates and Re-files Historical Financial Statements
TheNewswire.ca - Mon Jan 11, 7:30AM CST
(via Thenewswire.ca)
Helius Medical Technologies Announces Allowances of 10 New Patents
BusinessWire - Mon Jan 04, 4:43PM CST
Helius Medical Technologies, Inc. (CSE:HSM; OTCQB:HSDT) ("Helius", or the "Company", a medical technology company focused on the treatment of neurological symptoms caused by disease or trauma, announced today that ten (10) new patent applications (seven US and three Chinese) have been allowed by the US and Chinese Patent Offices in November and December 2015 building on the already strong patent portfolio of the company. The Company has a further 33 patents (22 US and 11 international) pending on its technology in the US and other markets around the world.
Helius Medical Technologies Announces Receipt of Remainder of A&B Funding, Changes to Board of Directors, and Extension of CRADA Agreement Through December 2017
BusinessWire - Thu Dec 31, 5:03PM CST
Helius Medical Technologies, Inc. (CSE:HSM; OTCQB:HSDT) ("Helius", or the "Company", a medical technology company focused on the treatment of neurological symptoms caused by disease or trauma, today announced that the Company has elected to draw down on the remaining USD $5 million credit facility from A&B (HK) Company Limited ("A&B", appointed two new members to its Board of Directors and obtained an extension to its Cooperative Research and Development Agreement ("CRADA" with the US Army Medical Research and Material Command ("USAMRMC".
Helius Medical Technologies Announces Positive Clinical Trial Results from its Multiple Sclerosis Pilot Study
BusinessWire - Mon Nov 02, 8:23AM CST
Helius Medical Technologies, Inc. (CSE: HSM; OTCQB: HSDT) ("Helius", or the "Company", a medical technology company focused on the treatment of neurological symptoms caused by disease or trauma, announced today that the Multiple Sclerosis ("MS" pilot study evaluating its investigational Portable Neuromodulation Stimulator ("PoNS(TM)" device, met all of its study objectives. A total of 14 subjects (7-active and 7-sham control) received treatment with the non-invasive brain stimulation technology and concomitant physiotherapy. The independent trial took place at the Montreal Neurological Institute and Hospital and Concordia University's PERFORM Center. The study objectives were to explore the potential beneficial effects of PoNS(TM) stimulation, as previously reported, and to provide data to be used for the design of future studies to support requests for marketing authorization. The study included the first use of Functional MRI ("fMRI" to measure the effect of PoNS(TM) while performing tasks with, and without, stimulation.
Helius Medical Technologies Appoints Thomas Griffin to Board of Directors and Chairman of the Audit Committee
Marketwire Canada - Mon Aug 08, 8:01AM CDT
NEWTOWN, PENNSYLVANIA--(Marketwired - Aug 8, 2016) - Helius Medical Technologies, Inc. (TSX:HSM)(OTCQB:HSDT) ("Helius" or the "Company"
a company focused on the treatment of neurological symptoms caused by disease or trauma, announced today that Thomas Griffin will join the Board of Directors, effective immediately. Mr. Griffin will also serve as Chairman of the Audit Committee. ENTL: 18.13 (-0.22), HSM.TO: 1.16 (unch)
Helius Medical Announces Results from a Case Series of Subjects With Advanced MS
Marketwire Canada - Tue Jun 21, 8:03AM CDT
NEWTOWN, PENNSYLVANIA--(Marketwired - Jun 21, 2016) - Helius Medical Technologies, Inc. (TSX:HSM)(TSX:HSM.S)(OTCQB:HSDT) ("Helius" or the "Company"
is pleased to announce the results of a case series of individuals with advanced symptoms of Multiple Sclerosis (MS) treated with PoNS™ Therapy. HSM.TO: 1.16 (unch), HSM-S.TO: 1.15 (-0.12)
Helius Medical Announces Proceeds of $1.4 Million From Exercise of Warrants
Marketwired - Mon Jun 06, 8:03AM CDT
NEWTOWN, PENNSYLVANIA--(Marketwired - Jun 6, 2016) - Helius Medical Technologies, Inc. (TSX:HSM)(OTCQB:HSDT) ("Helius" or the "Company"
a medical technology company focused on the treatment of neurological symptoms caused by disease or trauma, is pleased to announce that it received proceeds of CDN $1,825,600 (approximately US$1,409,947) from the exercise of certain warrants issued in 2014, all of which was received after the Company's fiscal year end on March 31, 2016. HSM.TO: 1.16 (unch)
Helius Medical Technologies Restates and Re-Files Historical Financial Statements for Non-Cash Reclassification of Warrants
Marketwired - Tue Apr 26, 4:06PM CDT
Helius Medical Technologies, Inc. (TSX: HSM)(OTCQB: HSDT) ("Helius" or the "Company"
- The Company is issuing the following press release to clarify its disclosure. HSM.TO: 1.16 (unch)
CSE: 2016-0408 - Delist - Helius Medical Technologies Inc. (HSM)
Marketwired - Mon Apr 18, 10:30AM CDT
The common shares of Helius Medical Technologies Inc. will be delisted at the market close today, April 18, 2016.
IIROC Trade Resumption - Helius Medical Technologies, Inc.
Newsfile Corp - Mon Apr 18, 8:25AM CDT
Trading resumes in:
IIROC Trade Resumption - HSM.S
CNW Group - Mon Apr 18, 8:24AM CDT
Trading resumes in:
IIROC Trade Halt - Helius Medical Technologies, Inc. Reg S Shares
Newsfile Corp - Mon Apr 18, 7:27AM CDT
The following issues have been halted by IIROC:
Helius Medical Technologies Restates and Re-files Historical Financial Statements
TheNewswire.ca - Mon Jan 11, 7:30AM CST
(via Thenewswire.ca)
Helius Medical Technologies Announces Allowances of 10 New Patents
BusinessWire - Mon Jan 04, 4:43PM CST
Helius Medical Technologies, Inc. (CSE:HSM; OTCQB:HSDT) ("Helius", or the "Company"
, a medical technology company focused on the treatment of neurological symptoms caused by disease or trauma, announced today that ten (10) new patent applications (seven US and three Chinese) have been allowed by the US and Chinese Patent Offices in November and December 2015 building on the already strong patent portfolio of the company. The Company has a further 33 patents (22 US and 11 international) pending on its technology in the US and other markets around the world. Helius Medical Technologies Announces Receipt of Remainder of A&B Funding, Changes to Board of Directors, and Extension of CRADA Agreement Through December 2017
BusinessWire - Thu Dec 31, 5:03PM CST
Helius Medical Technologies, Inc. (CSE:HSM; OTCQB:HSDT) ("Helius", or the "Company"
, a medical technology company focused on the treatment of neurological symptoms caused by disease or trauma, today announced that the Company has elected to draw down on the remaining USD $5 million credit facility from A&B (HK) Company Limited ("A&B", appointed two new members to its Board of Directors and obtained an extension to its Cooperative Research and Development Agreement ("CRADA" with the US Army Medical Research and Material Command ("USAMRMC". Helius Medical Technologies Announces Positive Clinical Trial Results from its Multiple Sclerosis Pilot Study
BusinessWire - Mon Nov 02, 8:23AM CST
Helius Medical Technologies, Inc. (CSE: HSM; OTCQB: HSDT) ("Helius", or the "Company"
, a medical technology company focused on the treatment of neurological symptoms caused by disease or trauma, announced today that the Multiple Sclerosis ("MS" pilot study evaluating its investigational Portable Neuromodulation Stimulator ("PoNS(TM)" device, met all of its study objectives. A total of 14 subjects (7-active and 7-sham control) received treatment with the non-invasive brain stimulation technology and concomitant physiotherapy. The independent trial took place at the Montreal Neurological Institute and Hospital and Concordia University's PERFORM Center. The study objectives were to explore the potential beneficial effects of PoNS(TM) stimulation, as previously reported, and to provide data to be used for the design of future studies to support requests for marketing authorization. The study included the first use of Functional MRI ("fMRI" to measure the effect of PoNS(TM) while performing tasks with, and without, stimulation. 
